SCHEMBL4201010

SCHEMBL4201010

O=c1c2nccnc2nc(-c2ccc(F)cc2)n1NCc1ccc(Cl)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
ADORA2A P29274 3/20 0.34
ADORA1 P30542 3/20 0.34
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
KCNK3 O14649 1/20 0.33
MAOB P27338 1/20 0.33
CES2 O00748 1/20 0.33
KDM5A P29375 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
PDE4A P27815 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
PTGES O14684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194181 0.88 ALDH1A1 (0.41) SMN1; SMN2ADORA2ALMNAMAPTHPGD
SCHEMBL4200373 0.82 SMN1; SMN2 (0.44) SMN1; SMN2ADORA2AMAPTHPGDMAOB
SCHEMBL4189608 0.81 KDM4E (0.42) SMN1; SMN2HPGDALDH1A1CYP1A2CYP2C9
SCHEMBL4200494 0.78 SMN1; SMN2 (0.48) SMN1; SMN2LMNAMAPTCES2HTT
SCHEMBL4202613 0.74 SMN1; SMN2 (0.48) SMN1; SMN2LMNAMAPTALDH1A1HTT
SCHEMBL4194316 0.73 AOC3 (0.37) DYRK1ACLK4LMNAHPGDALDH1A1
SCHEMBL4194122 0.72 ALDH1A1 (0.35) DYRK1ACLK4LMNAMAPTHPGD
SCHEMBL4199192 0.70 SMN1; SMN2 (0.48) SMN1; SMN2LMNAMAPTHPGDCES2
SCHEMBL4198926 0.70 SMN1; SMN2 (0.44) SMN1; SMN2LMNAMAPTALDH1A1HTT
SCHEMBL4202606 0.70 NR1I3 (0.43) SMN1; SMN2ADORA2AADORA1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 SMN1; SMN2 3183/4885DYRK1A 2758/4885CLK4 4594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.